UA5407U - Способ лечения атеросклероза - Google Patents
Способ лечения атеросклероза Download PDFInfo
- Publication number
- UA5407U UA5407U UA20040503693U UA2004503693U UA5407U UA 5407 U UA5407 U UA 5407U UA 20040503693 U UA20040503693 U UA 20040503693U UA 2004503693 U UA2004503693 U UA 2004503693U UA 5407 U UA5407 U UA 5407U
- Authority
- UA
- Ukraine
- Prior art keywords
- cholesterol
- treatment
- atherosclerosis
- course
- per
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 14
- 239000003613 bile acid Substances 0.000 claims abstract description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000037396 body weight Effects 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 claims abstract description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 5
- 229960001661 ursodiol Drugs 0.000 claims description 5
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 46
- 235000012000 cholesterol Nutrition 0.000 abstract description 21
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940078967 bile acid preparations for bile therapy Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000012762 regulation of cholesterol biosynthetic process Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения атеросклероза осуществляют путем дехолестеринизации атеросклеротически измененных сосудов. Применяют препарат желчной кислоты, который назначают внутривенно в дозе 2 мг на 1 кг массы тела один раз в неделю, причем количество инъекций составляет от 5 до 10 на курс лечения.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040503693U UA5407U (ru) | 2004-05-18 | 2004-05-18 | Способ лечения атеросклероза |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040503693U UA5407U (ru) | 2004-05-18 | 2004-05-18 | Способ лечения атеросклероза |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA5407U true UA5407U (ru) | 2005-03-15 |
Family
ID=74494250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040503693U UA5407U (ru) | 2004-05-18 | 2004-05-18 | Способ лечения атеросклероза |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA5407U (ru) |
-
2004
- 2004-05-18 UA UA20040503693U patent/UA5407U/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0909171B1 (en) | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 | |
| US7754692B2 (en) | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation | |
| RU2013110491A (ru) | Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных | |
| WO1997039759A2 (en) | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder | |
| CN107205976A (zh) | 用于治疗溶酶体病症的组合物和方法 | |
| JPH06145054A (ja) | 再灌流損傷を治療するための方法および組成物 | |
| WO2000040086A1 (en) | Formulations for treating disease and methods of using same | |
| JP2022088611A (ja) | オートファジーおよびリポファジーを調節するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法 | |
| US20210267251A1 (en) | Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor | |
| AU2009201384A1 (en) | Acetyl-L-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents | |
| US6344482B1 (en) | Omega-3 fatty acids in the treatment of bipolar disorder | |
| US6380252B1 (en) | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 | |
| CN87106235A (zh) | 治疗动脉粥样硬化的方法和基质组合物 | |
| UA5407U (ru) | Способ лечения атеросклероза | |
| US20040006048A1 (en) | Combination of lecithin with ascorbic acid | |
| US20130165453A1 (en) | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury | |
| ES2201128T3 (es) | Agente terapeutico para alteraciones del metabolismo de lipidos. | |
| US11786495B2 (en) | Medicinal properties of triethyl citrate | |
| RU2820163C2 (ru) | Композиции и способы с использованием по меньшей мере одного глицина или его производного, по меньшей мере одного n-ацетилцистеина или его производного и по меньшей мере одного никотинамидрибозида или предшественника nad+ | |
| RU2127589C1 (ru) | Способ лечения стрессорных поражений нервной системы | |
| Shamsov et al. | PREVENTION AND TREATMENT OF ANEMIC COMPLICATIONS AS A RESULT OF POLYCHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHLEOSIS | |
| Collins | CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin Amyloidosis | |
| Morozov et al. | The effect of 60-day administration of sodium benzoate and mexidol on the ultrastructure of the regenerate formed in the rat's tibiae | |
| EP3207939A2 (en) | Use of a protein/peptide complex for treating and preventing atherosclerosis, method for treating and preventing atherosclerosis (variants) | |
| Long et al. | Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice |